CL2015002705A1 - Anticuerpos anti-cd52. - Google Patents

Anticuerpos anti-cd52.

Info

Publication number
CL2015002705A1
CL2015002705A1 CL2015002705A CL2015002705A CL2015002705A1 CL 2015002705 A1 CL2015002705 A1 CL 2015002705A1 CL 2015002705 A CL2015002705 A CL 2015002705A CL 2015002705 A CL2015002705 A CL 2015002705A CL 2015002705 A1 CL2015002705 A1 CL 2015002705A1
Authority
CL
Chile
Prior art keywords
antibody
human
antibodies
understands
leukemia
Prior art date
Application number
CL2015002705A
Other languages
English (en)
Inventor
Huawei Qiu
Ronnie Rong Wei
Clark Qun Pan
Rebecca Sendak
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50391542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002705(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CL2015002705A1 publication Critical patent/CL2015002705A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ANTICUERPO ANTI-CD52 HUMANA, MOLECULA DE ACIDO NUCLEICO QUE LA CODIFICA; VECTOR RECOMBINANTE; LINEA CELULAR AISLADA; METODO PARA PREPARAR ANTICUERPO ANTI-CD52 HUMANA; COMPOSICION QUE COMPRENDE EL ANTICUERPO; USO PARA TRATAR CANCER, LEUCEMIA O ESCLEROSIS MULTIPLE.
CL2015002705A 2013-03-15 2015-09-14 Anticuerpos anti-cd52. CL2015002705A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361794576P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CL2015002705A1 true CL2015002705A1 (es) 2016-04-22

Family

ID=50391542

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002705A CL2015002705A1 (es) 2013-03-15 2015-09-14 Anticuerpos anti-cd52.

Country Status (36)

Country Link
US (2) US9708407B2 (es)
EP (1) EP2970467B1 (es)
JP (2) JP6482524B2 (es)
KR (1) KR20150131286A (es)
CN (1) CN105209495B (es)
AR (1) AR095199A1 (es)
AU (1) AU2014233685B2 (es)
BR (1) BR112015022464A2 (es)
CA (1) CA2906539A1 (es)
CL (1) CL2015002705A1 (es)
CR (1) CR20150547A (es)
CY (1) CY1121795T1 (es)
DK (1) DK2970467T3 (es)
DO (1) DOP2015000211A (es)
EA (1) EA031730B1 (es)
ES (1) ES2710976T3 (es)
GT (1) GT201500267A (es)
HK (1) HK1219963A1 (es)
HR (1) HRP20190085T1 (es)
HU (1) HUE041796T2 (es)
IL (1) IL241410A0 (es)
LT (1) LT2970467T (es)
MA (1) MA38485A1 (es)
MX (1) MX2015012991A (es)
NZ (1) NZ631473A (es)
PE (1) PE20151757A1 (es)
PH (1) PH12015501932A1 (es)
PL (1) PL2970467T4 (es)
PT (1) PT2970467T (es)
SG (1) SG11201506932SA (es)
SI (1) SI2970467T1 (es)
TN (1) TN2015000415A1 (es)
TR (1) TR201900638T4 (es)
TW (1) TWI644923B (es)
UY (1) UY35440A (es)
WO (1) WO2014151644A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201825115A (zh) 2009-05-13 2018-07-16 美商建新公司 抗人類cd52免疫球蛋白
CN110179989B (zh) 2009-05-13 2022-06-24 基酶有限公司 治疗狼疮的方法和组合物
PL3691169T3 (pl) * 2014-01-28 2022-07-25 Huawei Technologies Co., Ltd. Sposób wskazywania transmisji danych, punkt dostępowy i terminal
TW201841653A (zh) * 2017-04-21 2018-12-01 美商建新公司 以抗-cd52抗體治療多發性硬化症
MX2020008446A (es) * 2018-02-13 2020-09-28 Merck Sharp & Dohme Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.
WO2021022044A1 (en) * 2019-07-31 2021-02-04 Forty Seven, Inc. Depletion regimes for engineered t-cell or nk-cell therapy
WO2024038839A1 (ja) * 2022-08-15 2024-02-22 国立大学法人 東京大学 糸状菌を用いた免疫グロブリンまたは多量体免疫グロブリンの製造方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH0684377B1 (es) 1986-04-17 1994-10-26 Kyowa Hakko Kogyo Kk
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2598116B2 (ja) 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JP2510335B2 (ja) 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9108056D0 (en) 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5269388A (en) 1991-11-12 1993-12-14 Stress-Tek, Inc. Weighing bed
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
CA2165819C (en) 1994-04-22 2005-12-27 Nobuyoshi Amishiro Dc-89 derivatives
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
JP2003514903A (ja) 1999-11-24 2003-04-22 イムノージェン インコーポレーテッド タキサンを含有する細胞傷害薬とその治療への利用
EP1259615B1 (en) 2000-03-03 2008-11-12 Cambridge Antibody Technology Limited Antibodies against eotaxin and their use
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
AU2002362197A1 (en) 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
WO2004042032A2 (en) 2002-11-01 2004-05-21 The Ohio State University Research Foundation Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
CN1225480C (zh) 2002-12-18 2005-11-02 马菁 抗cd52单克隆抗体、其编码序列及应用
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
US20060228351A1 (en) 2003-03-31 2006-10-12 Junichi Masuyama Method of inducing differentiation and proliferating regulatory t cell by anti-cd52 antibody and medicinal composition therefor
US7498024B2 (en) 2003-06-03 2009-03-03 Cell Genesys, Inc. Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
EP1694706B1 (en) 2003-11-01 2012-04-04 Merck Patent GmbH Modified anti-cd52 antibody
US20060204496A1 (en) 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
BRPI0610304A2 (pt) 2005-05-24 2010-06-08 Avestha Gengraine Tech Pvt Ltd método recombinante para a produção de um anticorpo monoclonal para cd52 para o tratamento de leucemia linfocìtica crÈnica
ES2605945T3 (es) * 2005-05-27 2017-03-17 Biogen Ma Inc. Anticuerpos de unión a Tweak
EA200870130A1 (ru) 2005-12-30 2009-02-27 Мерк Патент Гмбх Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6
ES2423481T3 (es) 2006-04-12 2013-09-20 Genzyme Corporation Métodos de tratamiento de enfermedades autoinmunes
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
JP5872756B2 (ja) 2006-09-13 2016-03-01 アルカフロイ マネージメント ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト カンパス−１Ｈ（Ｃａｍｐａｔｈ−１Ｈ）による多発性硬化症（ＭＳ）治療
EP2417974A1 (en) * 2007-02-28 2012-02-15 Schering Corporation Combination therapy for treatment of immune disorders
WO2009000406A1 (en) 2007-06-22 2008-12-31 Bayer Healthcare Ag Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease
CN110179989B (zh) 2009-05-13 2022-06-24 基酶有限公司 治疗狼疮的方法和组合物
EP2429584A4 (en) 2009-05-13 2013-02-20 Genzyme Corp TREATMENT PROCEDURE AND COMPOSITIONS
TW201825115A (zh) * 2009-05-13 2018-07-16 美商建新公司 抗人類cd52免疫球蛋白
BR112012000953A8 (pt) * 2009-07-15 2017-12-26 Aimm Therapeutics Bv anticorpos de ligação a bactérias gram-positivas, sequência de ácido nucleico,seus usos e seu método de produção, células isolada ou produtora de anticorpo isolado ou recombinante, composições, e método de isolamento de bactérias
CN105734678B (zh) * 2010-07-16 2019-11-05 阿迪马布有限责任公司 合成多核苷酸文库

Also Published As

Publication number Publication date
AU2014233685A1 (en) 2015-10-01
MX2015012991A (es) 2015-12-15
JP2019069960A (ja) 2019-05-09
JP2016518333A (ja) 2016-06-23
AU2014233685B2 (en) 2019-02-28
TN2015000415A1 (en) 2017-01-03
PL2970467T3 (pl) 2019-07-31
CR20150547A (es) 2016-01-08
WO2014151644A2 (en) 2014-09-25
LT2970467T (lt) 2019-02-11
SI2970467T1 (sl) 2019-03-29
HRP20190085T1 (hr) 2019-03-08
NZ631473A (en) 2017-09-29
HK1219963A1 (zh) 2017-04-21
EP2970467A2 (en) 2016-01-20
PE20151757A1 (es) 2015-12-03
MA38485A1 (fr) 2017-06-30
ES2710976T3 (es) 2019-04-29
TW201522373A (zh) 2015-06-16
SG11201506932SA (en) 2015-09-29
GT201500267A (es) 2017-12-15
DOP2015000211A (es) 2015-11-30
CN105209495B (zh) 2020-06-26
BR112015022464A2 (pt) 2017-10-24
WO2014151644A3 (en) 2015-01-15
PL2970467T4 (pl) 2019-07-31
DK2970467T3 (en) 2019-02-11
UY35440A (es) 2014-10-31
IL241410A0 (en) 2015-11-30
KR20150131286A (ko) 2015-11-24
US20160024219A1 (en) 2016-01-28
CN105209495A (zh) 2015-12-30
EP2970467B1 (en) 2018-10-17
US20170349665A1 (en) 2017-12-07
JP6482524B2 (ja) 2019-03-13
PH12015501932A1 (en) 2016-01-04
CA2906539A1 (en) 2014-09-25
PT2970467T (pt) 2019-01-28
HUE041796T2 (hu) 2019-05-28
AR095199A1 (es) 2015-09-30
EA201591796A1 (ru) 2016-01-29
EA031730B1 (ru) 2019-02-28
CY1121795T1 (el) 2020-07-31
TWI644923B (zh) 2018-12-21
US9708407B2 (en) 2017-07-18
TR201900638T4 (tr) 2019-03-21

Similar Documents

Publication Publication Date Title
CL2021000716A1 (es) Constructos de anticuerpo para flt3 y cd3. (divisional sol. 201800269)
CY1123642T1 (el) Αντισωματα enanti-pd-1
CL2015002705A1 (es) Anticuerpos anti-cd52.
CY1124004T1 (el) Υποδορια σκευασματα αντισωματων αντι-cd38 και οι χρησεις τους
CL2021000717A1 (es) Constructos de anticuerpo para cd70 y cd3. divisional de solicitud 270-2018
CR20190330A (es) Anticuerpos anti-ox40 y sus usos
CL2020003416A1 (es) Constructos de anticuerpo biespecificos que se unen a mesotelina y cd3 (divisional sol. 201800268)
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
CL2020003409A1 (es) Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154)
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
BR112017020054A2 (pt) anticorpos para icos
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
CO2018000887A2 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3
EA202091540A1 (ru) Антитела к lilrb2
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
CL2016002004A1 (es) Anticuerpos anti-jagged1 y métodos de uso
MX2021010668A (es) Proteinas de fusion de citoquinas.
AR100255A1 (es) Un factor de secreción de proteínas con alta eficiencia secretora y un vector de expresión que lo comprende
CL2020001137A1 (es) Anticuerpos anti-apoc3 y métodos de uso de estos.
CL2016000351A1 (es) Método para la cuantificación de actinio-227 en composiciones de radio-223.
BR112017011285A2 (pt) compostos intermediários para produzir ingredientes de perfumaria
AR104413A1 (es) Anticuerpo de igf-1r y su utilización para diagnosticar cáncer
AR105560A1 (es) Constructos de anticuerpo para msln y cd3